3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
16
Colorectal Neoplasms
4
Brain Neoplasms
4
Neoplasms
3
Meningeal Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Colonic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Pathologic Complete Response
1
Metastatic Breast Cancer With a Isolated Brain Progression
1
Meningeal Carcinomatosis
1
Hemangiosarcoma
1
HER2-positive Gastric Cancer
1
HER2-positive Breast Cancer
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Pemetrexed
5
Bevacizumab
5
osimertinib
3
aflutinib
3
Temozolomide
3
trastuzumab deruxtecan
2
Topotecan
2
Spinal Puncture
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
tucatinib
1
trioctyl phosphine oxide
1
pembrolizumab
1
nimotuzumab
1
merphos
1
lenvatinib
1
glutathione pegylated liposomal doxorubicin
1
epothilone B
1
envafolimab
1
camrelizumab
1
XL647
1
Trastuzumab
1
Transplantation, Autologous
1
Radiotherapy
1
Radiosurgery
1
Nivolumab
1
Mental Status and Dementia Tests
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Meningeal Carcinomatosis
×
tucatinib
×
Clear all
NCT05800275
2025-11-18
ETIC-LM
UNICANCER
Phase 2
Recruiting
30 enrolled